{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:13:04Z","timestamp":1787170384454,"version":"build-2736575974"},"reference-count":14,"publisher":"Scientific Scholar","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Nephrol"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/0971-4065.114492","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T06:05:43Z","timestamp":1372831543000},"page":"271","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4"],"prefix":"10.25259","volume":"23","author":[{"given":"V","family":"Sakhuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PC","family":"Dheerendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HS","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0971-4065.114492-1","first-page":"1115","volume-title":"Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone","author":"Coco","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"key-10.4103\/0971-4065.114492-2","first-page":"149","volume-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","author":"Danese","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"key-10.4103\/0971-4065.114492-3","first-page":"2136","volume-title":"Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients","author":"Slatopolsky","year":"1984","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0971-4065.114492-4","first-page":"274","volume-title":"Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure","author":"Andress","year":"1989","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0971-4065.114492-5","first-page":"48","volume-title":"Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial","author":"Herrmann","year":"1994","journal-title":"Nephron"},{"key":"key-10.4103\/0971-4065.114492-6","first-page":"929","volume-title":"Low dose calcitriol versus placebo in patients with predialysis chronic renal failure","author":"Nordal","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/0971-4065.114492-7","first-page":"661","volume-title":"1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial","author":"Baker","year":"1989","journal-title":"Kidney Int"},{"key":"key-10.4103\/0971-4065.114492-8","first-page":"S22","volume-title":"New active analogues of vitamin D with low calcemic activity","author":"Brown","year":"1990","journal-title":"Kidney Int"},{"key":"key-10.4103\/0971-4065.114492-9","first-page":"156","volume-title":"Selective vitamin D analogs and their therapeutic applications","author":"Brown","year":"1994","journal-title":"Semin Nephrol"},{"key":"key-10.4103\/0971-4065.114492-10","first-page":"607","volume-title":"Effects of increasing doses of 1alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women","author":"Gallagher","year":"1994","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/0971-4065.114492-11","first-page":"877","volume-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","author":"Coburn","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"key-10.4103\/0971-4065.114492-12","first-page":"317","volume-title":"Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","author":"Tan","year":"1997","journal-title":"Kidney Int"},{"key":"key-10.4103\/0971-4065.114492-13","first-page":"550","volume-title":"Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism","author":"Fraz\u00e3o","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"key-10.4103\/0971-4065.114492-14","first-page":"532","volume-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: A sequential comparison","author":"Maung","year":"2001","journal-title":"Am J Kidney Dis"}],"container-title":["Indian Journal of Nephrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T15:36:56Z","timestamp":1712158616000},"score":1,"resource":{"primary":{"URL":"https:\/\/indianjnephrol.org\/efficacy-and-safety-of-oral-doxercalciferol-in-the-management-of-secondary-hyperparathyroidism-in-chronic-kidney-disease-stage-4\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"alternative-id":["114492"],"URL":"https:\/\/doi.org\/10.4103\/0971-4065.114492","relation":{},"ISSN":["0971-4065"],"issn-type":[{"value":"0971-4065","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}